CClinicalTrials.gg
CompletedNCT03840863Updated Nov 6, 2020

Effects of Chronic Energy Drink Consumption on Cardiometabolic Endpoints

An interventional study of Commercially-Available Energy Drink in Cardiovascular Diseases, sponsored by University of the Pacific. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by University of the Pacific · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Many people use energy drinks (EDs) regularly, but the overall health concerns are still unknown. There are many energy drink products that contain a mixture of caffeine and other energy-boosting ingredients and supplements which can affect parameters related to the heart, blood pressure and blood glucose. Several previous studies have shown that energy drinks may affect heart rhythm and blood pressure significantly. As energy drinks are sugar-sweetened beverages, long-term use may also affect the body's metabolism, including cholesterol, blood sugars, and weight.

The purpose of this study is to learn if drinking energy drinks everyday may affect a person's cardiometabolic health.

Read the detailed description

The popularity of energy drinks (EDs) have increased over the last few decades due to their purported benefits as mental and physical performance enhancements. While caffeine is a major ingredient in most EDs (ranging from 80 mg to 500 mg per drink), they may also contain various supplements, such as guarana, taurine, ginseng, B vitamins, gluconolactone, yohimbe, carnitine, and bitter orange, as well as high amount of sugar (ranging from 25-50 grams). The United States Food and Drug Administration (FDA) has cited that a daily intake of 400 mg caffeine (approximately 4-5 cups of coffee) in adults is generally safe and not associated with dangerous, negative effects. The Substance Abuse and Mental Health Services Administration reported a doubling of emergency department visits involving EDs from 10,068 visits in 2007 to 20,783 visits in 2011. Commonly reported adverse reactions include insomnia, nervousness, headache, tachycardia, and seizures. Currently, the health effects of long-term ED use remain unknown.

This study is a proof-of-concept, prospective trial that aims to evaluate the effects of chronic ED consumption on cardiometabolic parameters in a healthy population. Subjects will consume two cans (16 oz.) of an energy drink daily for 4 weeks. The study will assess any changes in blood pressure (BP), electrocardiographic (ECG) parameters, blood glucose, cholesterol, weight, body mass index (BMI), and body fat composition before and after consuming EDs for 4 weeks.

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • Energy Drink
  • Blood Pressure
  • Arrhythmia
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 15 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of the Pacific is the lead sponsor of 16 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adults aged 18 - 40 years
  • Participants willing to adhere to study drink schedule (28 days)

Exclusion criteria

Exclusion Criteria:

  • Naïve caffeine consumers (\< 2 cups of coffee [or equivalent caffeine intake] per week)
  • Chronic medical conditions including cardiovascular disease (known history of cardiac arrhythmias, family history of premature sudden cardiac death before age 60, cardiomyopathy, atherosclerosis), smoking, renal or hepatic dysfunction
  • Prolonged corrected QT (QTc) interval
  • History of substance abuse, including alcohol
  • Concurrent use of prescription drugs or over-the-counter products that may interact with study drinks (with the exception of oral contraceptives that have been used for over 1 month)
  • Baseline Blood Pressure greater than 140/90 mmHg
  • Baseline fasting blood glucose greater than 126 mg/dL or random blood glucose greater than 200 mg/dL
  • Females only: pregnancy or lactation, or planning to get pregnant within next 28 days
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Commercially-Available Energy drink

    Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks

    Dietary Supplement: Commercially-Available Energy Drink

Interventions

  • Dietary supplementCommercially-Available Energy Drink

    Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.

06

What researchers measure

Primary outcomes

  1. Change in blood pressure before and 1 hour after energy drink consumption

    Measuring acute changes in peripheral systolic blood pressure before and 1 hour after energy drink consumption

    Time frame: 1 hour

  2. Change in blood pressure before and after 4 weeks of energy drink consumption

    Measuring chronic changes in peripheral systolic blood pressure before and 4 weeks after energy drink consumption

    Time frame: 4 weeks

Secondary outcomes

  1. Change in QTc Interval before and after 1 hour of energy drink consumption

    Measuring change in QTc interval via electrocardiogram before and after 1 hour of energy drink consumption

    Time frame: 1 hour

  2. Change in QTc Interval before and after 4 weeks of energy drink consumption

    Measuring change in QTc interval via electrocardiogram before and after 4 weeks of energy drink consumption

    Time frame: 4 weeks

  3. Change in fasting blood glucose before and after 4 weeks of energy drink consumption

    Measuring the change in fasting blood glucose before and after 4 weeks of energy drink consumption

    Time frame: 4 weeks

  4. Change in fasting lipid panel parameters before and after 4 weeks of energy drink consumption

    Measuring the changes in total cholesterol (TC), high-density lipoprotein (HDL), triglyceride (TG), and calculated low-density lipoprotein (LDL-C) levels before and after 4 weeks of energy drink consumption

    Time frame: 4 weeks

  5. Change in Body Mass Index before and after 4 weeks of energy drink consumption

    Measuring the change in Body Mass Index (BMI) before and after 4 weeks of energy drink consumption

    Time frame: 4 weeks

  6. Change in Body Fat Analysis before and after 4 weeks of energy drink consumption

    Measuring the changes in Body Fat Analysis before and after 4 weeks of energy drink consumption, including percentage of body fat, fat mass, muscle mass, and fat in trunk

    Time frame: 4 weeks

  7. Change in Serum Creatinine before and after 4 weeks of energy drink consumption

    Measuring the change in Serum Creatinine before and after 4 weeks of energy drink consumption

    Time frame: 4 weeks

07

Study locations

1 site
  • University of the Pacific
    Stockton, California 95211, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03840863
Lead sponsor
University of the Pacific
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Mar 6, 2019
Primary completion
Jun 20, 2019
Completion
Jul 30, 2020
Last update
Nov 6, 2020

Study contacts

May Chen, PharmD
principal investigator · University of the Pacific

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion